Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

557P - Binimetinib, pemetrexed (Pem) and cisplatin (Cis), followed by maintenance of Binimetinib and Pem in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations: The phase Ib SAKK 19/16 trial

Date

17 Sep 2020

Session

E-Poster Display

Topics

Clinical Research

Tumour Site

Thoracic Malignancies

Presenters

Patrizia Froesch

Citation

Annals of Oncology (2020) 31 (suppl_4): S462-S504. 10.1016/annonc/annonc271

Authors

P.R. Froesch1, M.T. Mark2, S.I. Rothschild3, Q. Li4, G. Godar4, C. Rusterholz4, S. Schmid5, I. Colombo1, Y. Metaxas2, H.E. Thut3, C. Sessa1, O. Gautschi6, M. Früh5

Author affiliations

  • 1 Medical Oncology, Oncology Institute of Southern Switzerland, 6500 - Bellinzona/CH
  • 2 Oncology/hematology Department, Cantonal Hospital Graubünden, 7000 - Chur/CH
  • 3 Medical Oncology, University Hospital Basel, 4031 - Basel/CH
  • 4 Cc, SAKK, 3008 - Bern/CH
  • 5 Department Of Oncology/hematology, Cantonal Hospital St. Gallen, 9007 - St. Gallen/CH
  • 6 Medical Oncology, Cantonal Hospital Lucerne, 6004 - Lucerne/CH

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 557P

Background

KRAS mutations are found in 20-25% of non-squamous NSCLC and effective therapies targeting the RAS/MEK/ERK pathway are needed. Binimetinib an oral selective MEK Inhibitor plus platinum-based chemotherapy is promising. We design a multicenter open-label phase IB trial to define the recommended phase II dose and early efficacy of Binimetinib in combination with Pem and Cis.

Methods

Eligible patients (pts) had: stage III-IV NSCLC unsuitable for curative treatment, performance status (PS) 0-1, KRAS exons 2 or 3 (codon 12, 13 or 61) mutations, no prior systemic therapy. Pts were enrolled into part 1: 3+3 design with dose escalation in 2 dose levels (DL) of Binimetinib and part 2: expansion cohort at the maximum tolerated DL. Treatment consisted of 4 cycles of Cis 75 mg/m2, Pem 500 mg/m2 and Binimetinib 30 (DL1)/45 mg (DL2) BID d1-14 (d3-14 in cycle 1) q3w followed by Pem and Binimetinib until progressive disease (PD) or unacceptable toxicity.

Results

From May 2017 to Dec 2019, 18 pts (13 in part 1, 5 in part 2) were enrolled. Median age was 56 years (48–73), 56% were male, 65% had PS 1. KRAS mutations were 83% at codon 12, 6% at codon 13 and 6% at codon 61. In part 1, 9 pts (3 in DL1, 6 in DL2) were evaluable for DLT and no DLT occurred. Median number of cycles was 2 (1-17, range). All pts are off treatment mainly due to PD (30%) or pts/physicians decision (30%). Together with part 2, 10 pts received 45 mg Binimetinib, one of which was excluded from efficacy due to eligibility violation. Overall response rate was 33% (7 – 70%, 95% CI). Median progression-free survival and overall survival were 5.7 months (1.1 - 14.0, 95% CI) and 6.5 months (1.8 – NR, 95% CI), respectively. No grade 4/5 adverse events (AEs) were observed. Most common treatment-related grade 3 AEs were fatigue (30%), nausea, anemia, hypertension and lung infection (20% each). One patient experienced a grade 3 thromboembolic event. No grade 3 ocular or cardiac AE occurred.

Conclusions

The combination of Cis, Pem and Binimetinib at 45mg BID was safe. No early signal of increased efficacy of the addition of Binimetinib to chemotherapy was observed in KRAS-mutant NSCLC.

Clinical trial identification

NCT02964689.

Editorial acknowledgement

Legal entity responsible for the study

Swiss Group for Clinical Cancer Research (SAKK).

Funding

Array BioPharma Inc.

Disclosure

P.R. Froesch: Honoraria (self), Advisory/Consultancy: Pfizer; Honoraria (self), Advisory/Consultancy: Roche; Honoraria (self), Advisory/Consultancy: Takeda; Honoraria (self), Advisory/Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy: BMS. M.T. Mark: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): AstraZenca; Honoraria (self), Advisory/Consultancy: BMS; Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self), Advisory/Consultancy: Roche; Honoraria (self), Advisory/Consultancy: Takeda. S.I. Rothschild: Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): AstraZenca; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): BMS; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Merck Serono; Honoraria (self), Advisory/Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy: Pfizer; Honoraria (self), Advisory/Consultancy: Eisai; Honoraria (self), Advisory/Consultancy: Eli Lilly; Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy: Roche; Honoraria (self), Advisory/Consultancy: Takeda. S. Schmid: Research grant/Funding (self): AstraZenca; Research grant/Funding (self): BMS; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Boehringer Ingelheim; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: MSD; Travel/Accommodation/Expenses: Takeda. O. Gautschi: Honoraria (self), Advisory/Consultancy: Amgen; Research grant/Funding (institution): Eli Lilly; Research grant/Funding (institution): Roche; Research grant/Funding (institution): Novartis; Research grant/Funding (institution): AbbVie. M. Früh: Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): BMS; Honoraria (institution), Advisory/Consultancy: MSD; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): AstraZenca; Honoraria (institution), Advisory/Consultancy: Boehringer Ingelheim; Honoraria (institution), Advisory/Consultancy: Roche; Honoraria (institution), Advisory/Consultancy: Takeda. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.